Ratnakar Securities Pvt. Ltd.

MANKIND PHARMA LTD.

NSE : MANKINDBSE : 543904ISIN CODE : INE634S01028Industry : Pharmaceuticals & DrugsHouse : Private

BSE2314.30-19.75 (-0.85 %)

PREV CLOSE ( ) 2334.05

OPEN PRICE ( ) 2347.30

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 10964

TODAY'S LOW / HIGH ( )2305.00 2350.00

52 WK LOW / HIGH ( )1240.75 2488.65

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 03-07 1991

Management Info

Ramesh Juneja - Chairman Rajeev Juneja - Managing Director

Registered Office

Address 208,Okhla Industrial Estate,Phase - 111,
New Delhi,
Delhi-110020

Phone 011-46846700

Email investors@mankindpharma.com

Website www.mankindpharma.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

14Mar Mankind Pharma informs about investor
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..

12Mar Rail Vikas Nigam, NBCC and Mankind Pha
Rail Vikas Nigam has emerged as the Lowest Bidder (L1) from Central Rail..

12Mar Mankind Pharma inches up on inking pac
Mankind Pharma is currently trading at Rs. 2165.60, up by 3.30 points or..

11Mar Mankind Pharma inks pact with AstraZen
Mankind Pharma has entered into an agreement with AstraZeneca Pharma Ind..

11Mar Mankind Pharma informs about press rel
Mankind Pharma has informed that Mankind Pharma & AstraZeneca Pharma..

Financials

in Millions

	QTR Dec 23	ANNUAL 23
Net Profit	4870.74	12482.57
Gross Profit	5763.52	15628.36
Operating Profit	6703.4	18601.64
Net Sales	23585.66	81271.53

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Ajanta Pharma (BSE) 2377.00 (6.44%)	M.Cap ( in Cr)29930.39
Alkem Laboratories (BSE) 4899.45 (2.36%)	M.Cap ( in Cr)58580.27
Astrazeneca Pharma I (BSE) 5424.45 (1.70%)	M.Cap ( in Cr)13561.13
Dr. Reddy's Lab (BSE) 6349.95 (0.98%)	M.Cap ( in Cr)105928.76
Torrent Pharma (BSE) 2732.60 (2.20%)	M.Cap ( in Cr)92483.60

Shareholding Pattern

	MUTUAL FUNDS/UTI	8.57%
	PROMOTERS	74.88%
	NON-INSTITUTION	4.11%
	FI/BANKS/INSURANCE	2.17%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Invesco India Focus...	5.28
SBI Healthcare Opp ...	5.26
WOC Pharma and Heal...	5.23
ITI Pharma & Health...	5.15
Bandhan Focused Equ...	4.90
Edelweiss Recently ...	4.29

attention investors
kyc
ipo
ibt trading

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

MANKIND PHARMA LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES